| 前收市價 | 6.10 |
| 開市 | 5.35 |
| 買盤 | 5.50 |
| 賣出價 | 5.90 |
| 拍板 | 47.50 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 5.35 - 5.43 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 725 |
ZacksFDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
ZacksIonis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Zacks
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
